Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083893 | 0.94 | CNR2 (0.50) | FAAHCNR2MAPTTP53MEN1 | |
| SCHEMBL3005273 | 0.92 | FAAH (0.49) | FAAHCNR2TP53MEN1HTT | |
| SCHEMBL3008221 | 0.91 | FAAH (0.49) | FAAHCNR2TP53MEN1HTT | |
| SCHEMBL3000282 | 0.89 | FAAH (0.49) | FAAHCNR2TP53MEN1HTT | |
| SCHEMBL4083374 | 0.89 | FAAH (0.52) | FAAHCNR2MAPTMEN1HTT | |
| SCHEMBL2991276 | 0.89 | ALDH1A1 (0.57) | FAAHCNR2MAPTMEN1KMT2A | |
| SCHEMBL3001079 | 0.89 | MAPT (0.47) | FAAHCNR2MAPTMEN1HTT | |
| SCHEMBL4094014 | 0.88 | TP53 (0.52) | FAAHCNR2MAPTTP53HTT | |
| SCHEMBL3006611 | 0.88 | FAAH (0.46) | FAAHCNR2TP53MEN1HTT | |
| SCHEMBL3000642 | 0.87 | FAAH (0.51) | FAAHCNR2MAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | claimed |
| EP-2007703-B1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INT UK LTD (GB) | 2013-12-18 | — | — | EP | claimed |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-08-05 | — | — | US | claimed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| EP-2513031-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8785678-B2 | Continuous process for the carbonylation of ethylene | LUCITE INTERNATIONAL UK LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20120309613-A1 | CARBONYLATION PROCESS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120277474-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | SCD, ELOVL6, ALK | FAAH 207/4885CNR2 720/4885MAPT 3022/4885 |
| US-20120277474-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | CCNE2, CYC1, ETFB | FAAH 3865/4885CNR2 1509/4885MAPT 2041/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | FAAH 109/4885CNR2 20/4885MAPT 997/4885 |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | ALOX5, ACSL5, ELOVL5 | FAAH 1364/4885CNR2 192/4885MAPT 4753/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885CNR2 3/4885MAPT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.